Zevra Therapeutics, Inc. (ZVRA) Earnings Call Transcript & Summary

November 3, 2026

NASDAQ US Health Care Pharmaceuticals earnings 43 min

Earnings Call Speaker Segments

Nichol Ochsner

executive
#1

Thank you, and hello to everyone who has joined us. On today's agenda, we'll first walk through what we've achieved lately, and after that we'll go over the financial results for our third quarter of 2026. Please take a moment to look at our earnings release, which went out this afternoon and can be found in the Investors section of our website. Before we get started, I want to point out that some of what we discuss today will contain forward-looking statements. Because of the risks and uncertainties tied to Zevra's business, actual results could differ materially from what those statements state or imply. Forward-looking statements aren't promises or guarantees, and by their nature they carry risks, uncertainties and other significant factors that could cause actual results to differ materially from the projections made; they should be considered alongside the Risk Factors section of our latest quarterly report on Form 10-Q, our annual report on Form 10-K, and our other filings with the SEC. I'm happy to introduce the members of Zevra's management team who are with us on today's call. Neil McFarlane, Zevra's President and Chief Executive Officer; Joshua Schafer, our Chief Commercial Officer; and Justin Renz, our Chief Financial Officer; and now I'm glad to turn the call over to Neil.

Neil McFarlane

executive
#2

Thanks, Nichol, and good afternoon to everyone joining us for this quarterly call. At Zevra, we're a purpose-driven organization that's redefining what's achievable and delivering life-changing therapies to individuals facing rare diseases; within rare disease, the journey is complicated. The needs are pressing and the responsibility is considerable. Those individuals and families behind these needs sit at the center of our daily work. Momentum from the U.S. launch of MIPLYFFA—the first approved therapy for Niemann-Pick disease Type C, or NPC—mirrors the disciplined execution of our strategic plan along with the determination, expertise, and dedication of our team. Together, we're building a trusted company equipped with the capabilities and resolve needed to create a lasting difference. I'm happy to report that total net revenue for the third quarter reached $37.8 million, up 45% versus the third quarter of 2025, while net U.S. product revenue for MIPLYFFA came in at $34 million. What the market is showing us indicates this could be only the start, especially as we deepen our knowledge of the NPC community across the United States, where an estimated 900 individuals live with NPC, and of those, 300 to 350 have received a diagnosis. These figures come from a study published in 2021, before any approved treatment for NPC existed. During the third quarter, we obtained 13 prescription enrollment forms, which brings the cumulative total since launch to 197. When it comes to rare disease, the number of patients who get identified often climbs as time passes — awareness increases, more people receive diagnoses, and additional therapies win approval. Later in this call, Josh will go into greater detail about the ways our efforts are moving patient identification, diagnosis, and treatment forward. Our commitment to realizing MIPLYFFA's full potential and to backing the NPC community is driving our investment in expanding patient access. During the second quarter, we released findings from a multicenter, open-label pediatric substudy that looked at treating NPC with arimoclomol together with miglustat in infants ranging from 6 months to under 24 months of age. That substudy measured safety and tolerability across as much as 36 months of treatment and determined that arimoclomol was well tolerated, with no new safety signals observed. Following that, during the third quarter, we met with the FDA in a Type B meeting to investigate the possibility of broadening the label to cover infants under 24 months of age. Given the feedback, we anticipate submitting an sNDA in the first quarter of 2027. Equally important, we believe MIPLYFFA benefits from a robust intellectual property portfolio. MIPLYFFA has patents listed in the Orange Book with expiration dates running through 2041, plus U.S. orphan drug exclusivity for treating NPC through 2031. So those provide two distinct forms of protection for us: exclusivity that comes from the regulatory side, plus coverage under our listed patents. During previous calls we've mentioned that we are also pursuing a possible patent term extension through the U.S. Patent and Trademark Office. With the processing timelines as they currently stand, our expectation now is a USPTO decision in 2027. Meanwhile in the EU, the Committee for Medicinal Products for Human Use, or CHMP, is handling the reexamination of our Marketing Authorisation Application, or MAA, for arimoclomol. For that reexamination, a fresh rapporteur and co-rapporteur have been appointed to lead the CHMP's evaluation. Beyond that, a temporary panel of specialists—referred to as AHEG—will meet to review the findings and contribute its focused scientific and medical know-how. This serves as an important venue where professionals in the discipline can provide viewpoints that will inform the CHMP's discussions of its process. In our view, the combined clinical and real-world evidence backs the meaningful benefits for patients observed with arimoclomol. The considerable unmet need across Europe pushes us to continue our efforts for those living with NPC, and we anticipate the CHMP's opinion during the fourth quarter. Since the AHEG and CHMP sessions fall so near each other, our responses to questions regarding the ongoing procedure will be kept brief. Now regarding our Global Expanded Access Program, or EAP. Our dedication to the NPC community and to helping eligible patients obtain arimoclomol remains unwavering. The global EAP, which consists of compassionate use and named patient reimbursement programs, has 134 patients enrolled. As we've said before, reimbursement figures for each quarter shift depending on when orders are placed and how frequently they occur. Notably, during the last quarter we added another territory to the program and are still assessing further opportunities to broaden patient access worldwide. Turning to the late-stage pipeline. Celiprolol is under evaluation as a treatment for vascular Ehlers-Danlos syndrome, or vEDS. vEDS is a rare inherited disorder of connective tissue that results from a mutation in the COL3A1 gene. This mutation makes blood vessel walls and certain follow organs fragile, which can lead to arterial rupture or dissection, along with other complications. Through our Phase 3 DiSCOVER trial, we are working to confirm that celiprolol, our selective adrenoceptor modulator, can lessen the mechanical stress placed on these tissues and in that way reduce the likelihood of a major event. During the third quarter, we enrolled six new patients, bringing the total to 72. As a reminder, the trial was designed with an interim analysis triggered at 28 events, and four events had been confirmed as of the end of Q3. As we've mentioned before, our priority is moving the DiSCOVER trial forward, and we're looking at ways to speed up the program through conversations with the FDA. After a Type C meeting during the first quarter, we more recently completed a second Type C meeting to talk over a possible submission strategy that would incorporate real-world data sets. We're waiting on the official minutes from that meeting to verify what comes next, and in the meantime we're putting together a statistical analysis plan that brings in the retrospective data sets, with the goal of holding a follow-up discussion with the agency during the first half of 2027. Throughout the business, we continue to concentrate on pushing key opportunities ahead while keeping our financial position strong. We ended Q3 with over $270 million across cash, cash equivalents and investments, and that gives us what we see as the flexibility to go after near-term opportunities with MIPLYFFA here in the U.S., to broaden patient access in global markets, and to keep moving our development pipeline forward. At this point I'll turn things over to Josh for a look at our commercial momentum. Josh?

Joshua Schafer

executive
#3

Thank you, Neil. We keep laying the groundwork for durable MIPLYFFA expansion by identifying patients, raising disease awareness and engaging stakeholders. That progress shows up not just in the 197 prescription enrollment forms submitted since launch, but also in our wider activity and rising awareness throughout the NPC community. During the third quarter, the 13 prescription enrollment forms we received reflected a mix of adult and pediatric patients, along with a meaningful share of newly diagnosed patients. As a reminder, NPC is a fatal lysosomal storage disorder that causes abnormal lipid accumulation, which over time produces progressive dysfunction of the nerves, brain and other organs. This leads to neurodegenerative and visceral symptoms, including negative effects on speech, cognitive function, fine motor skills and the ability to swallow. Symptoms differ from patient to patient, and many people with NPC go a prolonged period before diagnosis because of limited disease awareness. Disease progression cannot be reversed and varies according to the age at symptom onset. MIPLYFFA together with miglustat is established as a foundational treatment for NPC and has shown a halting of disease progression at 12 months and rapid improvement by the first assessment at week 12 on the NPC clinical severity scale; recently published clinical practice guidelines further reinforce this, as does real-world evidence confirming MIPLYFFA's long-term efficacy and safety profile. We published new data in the third quarter, and at the recent SSIEM Annual Symposium, findings from our Early Access programs were presented showing sustained disease stabilization across age groups, adults included. Since launch, we have seen high patient retention and refill rates, consistent with what we saw in our EAP study. This data helps support our market access position and payer coverage, which currently stands at 69%. Most of the remaining patients obtain coverage through medical exception pathways. This broad coverage is made possible by our ongoing dialogues and engagement with payers, including regular presentations and conference participation. Our integrated commercial strategy centers on finding new patients, speeding up their diagnosis and widening access to treatment. Because NPC symptoms vary widely, diagnosing the disease can be difficult. We support overall disease awareness through our campaign called Learn NPC, Read Between the Signs. We also support early diagnosis by collaborating with genetic testing providers. In addition, we identify healthcare professionals who may be treating NPC patients using our proprietary analytics model, and we engage these professionals in discussions focused on disease awareness and relevant treatment options. Many of these clinicians may be treating their first and perhaps only NPC patient. To facilitate education and deepen understanding of treatment options, our Expert Connect program gives clinicians with less NPC experience direct access to experts in the field. We are encouraged by the impact of these efforts. Our digital presence spans multiple platforms, including the disease awareness website, the MIPLYFFA branded website and our patient and caregiver channels. During the third quarter, traffic rose across every digital channel, with gains in display impressions, search clicks, and click-through rates among HCP and patient audiences. More specifically, our disease awareness website produced strong results, posting a 123% increase in site visits quarter-over-quarter, from 25,000 in Q2 to nearly 56,000 in Q3. That was driven in part by the launch of our new NPC Knowledge Hub, which offers educational resources for patients and caregivers. These results show some of the impact we are having in expanding disease awareness and supporting Zevra's focus on accelerating time to NPC diagnosis — activities that have directly led to enrollments. In addition, we broadened our engagement with the NPC patient advocacy community and strengthened our scientific leadership by participating in national and regional congresses. During the quarter, we also held scientific steering committee meetings with NPC experts to gather input on diagnosis, treatment decision-making, and long-term disease management. Based on analysis of medical claims data, we believe the number of individuals with NPC in the U.S. may be higher than previous estimates. With our flexible commercial model, we can scale quickly to respond to new information. As a result, we modestly expanded our customer-facing teams to broaden our reach in community practices outside of the centers of excellence, where we continue to focus. Taken together, these efforts reflect a comprehensive approach to connecting patients with appropriate treatments and access. We're grateful for our partnerships across the NPC community and proud to support those living with this devastating disease. With that, I'll turn the call over to Justin.

Justin Renz

executive
#4

Appreciate that, Josh. To start, I want to point listeners to the Form 10-Q quarterly report we plan to file later today, since it has fuller financial detail. Thanks to revenue growth and a robust balance sheet fueled by MIPLYFFA, we feel our financial base is strong enough to sustain continuing operations while we carry out our corporate priorities. Net revenue on a total basis for Q3 2026 reached $37.8 million, an increase of $11.7 million, or 45%, compared with $26.1 million during Q3 2025. Within that figure, U.S. net sales of MIPLYFFA accounted for $34 million, OLPRUVA contributed $0.2 million, and net reimbursements from the global EAP added $3.6 million. U.S. MIPLYFFA's revenue climbed 12.6% compared with this year's second quarter, and it was up 52% against the third quarter of last year. Operating expenses for the third quarter of 2026 came to $24.1 million, which is $3.7 million more than in the same quarter the prior year. R&D expense in Q3 2026 totaled $4.9 million, an increase of $1.5 million from Q3 2025, driven mainly by continued investment in arimoclomol as well as the celiprolol development program. SG&A expense for Q3 2026 reached $19.1 million, $2.2 million higher than Q3 2025, largely because of commercial and infrastructure-related costs. In Q3 2026, we recorded an income tax provision of $0.5 million. For Q3 2026, net income came in at $19.2 million, equal to $0.31 per basic share and $0.26 per diluted share. That compares with a net loss of $0.5 million, or $0.01 per basic and diluted share, in the same quarter last year. During the third quarter, we booked a favorable noncash mark-to-market fair value credit of $5.5 million tied to our outstanding common stock warrants; this appears within the other income section of our consolidated statements of operations. At September 30, 2026, cash, cash equivalents and investments totaled $270.9 million, roughly $10.7 million higher than the June 30, 2026 level. To wrap up, our balance sheet remains solid, giving us both the ability and the adaptability to move our strategic priorities forward. At this point, I'll hand things back to Neil for his closing comments. Neil?

Neil McFarlane

executive
#5

Thanks, Justin. We feel we're in a strong position to keep building on the momentum we have with MIPLYFFA in the U.S., to broaden access to arimoclomol around the world, and to pursue the path that could speed up celiprolol's development. With a solid corporate foundation supporting our strategic plan and a shared commitment to putting patients first, we are dedicated to making a meaningful impact for all Zevra stakeholders. Operator, please open the line for questions.

Kristen Kluska

analyst
#6

I had a couple of those. First question: in your prepared remarks, you mentioned that with your strong cash position, you're exploring near-term opportunities for MIPLYFFA in the U.S. I was hoping you could go into more detail on that. Is it driven by the — your comments regarding the sNDA, pardon me?

Neil McFarlane

executive
#7

Kristen, I'm not certain I grasped the question, but let me try to answer it in two ways. First, yes, we are examining near-term opportunities for MIPLYFFA, and the fact that we published our pediatric substudy earlier this year. Following that, we approached the agency to explore a Type B meeting and the chance to potentially broaden the label to cover patients under 24 months of age. That feedback genuinely shaped our strategy to proceed with the planned sNDA in Q1 of '27. So we do believe that represents a great opportunity, particularly now that we have this intellectual property Orange Book listing, as we noted last quarter, running out to 2041.

Kristen Kluska

analyst
#8

Then I have just one question about the U.S. commercial launch. With today's new numbers, it looks like together you've reached roughly 2/3 of the U.S. patient population, which is genuinely impressive in a little more than a year. Looking ahead, I'm curious how we should be setting expectations. Do you still believe there's more to unlock among patients already diagnosed? Or should we think that most near-term new enrollment forms will really be driven by potential new patient adds?

Neil McFarlane

executive
#9

Yes. Thanks, Kristen. So yes, you're right. Since launching, over the first seven complete quarters, we've managed to reach a substantial share — you mentioned two-thirds — of the diagnosed patient population. What's encouraging about the current picture, and what gives us considerable confidence that we sit somewhere in the range of 350 to 900 patients in the United States, is how much we're learning. We're seeing patients who are newly diagnosed. We can see what our efforts are producing, and I'll have Josh go into more detail on some of the specifics—what we're learning with adult patients and with pediatric patients, split roughly 50% each—and that we've now found the market we expect is estimated to be larger than we first anticipated, in that 350 to 900 range. So there's still a great deal of ground to cover, but I'll let Josh discuss some of these learnings and, frankly, why we made this modest expansion.

Joshua Schafer

executive
#10

Yes. Kristen, thank you for that question. As we mentioned, since launch we've had 197 enrollments, and it's been genuinely encouraging to see such a solid split between pediatric and adult patients. On top of that, each quarter we're seeing a fairly consistent influx of new patients. Then, added to all of this, the claims data analysis we're conducting — which we've been examining quite closely — indicates that more patients exist than our initial estimate suggested; so we've grown our sales team in order to locate those patients. It's still early, but we're confident those patients are out there and that the market potential could be bigger than we first estimated.

Sumant Kulkarni

analyst
#11

I've got three. You made a few qualitative points during your prepared remarks, but since the figures for diagnosed and treated patients and the prevalence data were as of 2021, what's your current view on how much larger those numbers might be now that MIPLYFFA has been approved for a little over two years in the U.S.? And what share of the patient population is under 24 months of age?

Neil McFarlane

executive
#12

Let me try to kick that off and then ask Josh to handle some of the specifics. Sumant, we've brought this up several times over the past 1.5 years. And often, what happens when you launch a product for the first time in a rare disease is that you begin to see the tide rising, so to speak, and you see newly diagnosed patients coming in — which is what we've now observed for roughly the last five quarters straight, a meaningful number of newly diagnosed patients in addition to children and adults. And you begin to see some of the disease state awareness, with the integrated strategy lifting awareness of the disease area, and you start to get more patients diagnosed. I think this all — and much of these learnings are really what's driving our confidence that the market of what we believed were the 300 to 350 diagnosed patients, but with a prevalent number around 900, we're now beginning to see that tide rising and enabling us to see somewhere between that 350 and 900; so I'll ask Josh to speak a bit about what the 2021 publication, which is what we cite, versus some of the learnings we've seen over roughly the last seven quarters.

Joshua Schafer

executive
#13

Yes. So those initial figures came from a 2021 publication that took a retrospective look at claims data involving patients diagnosed with NPC; and then, jumping ahead five years to now, what we're seeing is — well, first, the dataset is far more comprehensive than before; but also, as Neil mentioned, the launch of MIPLYFFA has brought greater disease awareness. And as we noted, our disease awareness campaign has roughly doubled site visits, for both clinicians and patients. I think all of that is genuinely helping to build greater awareness of NPC. Diagnosis rates are climbing as well. So all of that gives us confidence that the number exceeds the original estimate.

Neil McFarlane

executive
#14

I believe you had a question as well. Sorry about that, Sumant — I think you were also raising something about the pediatric population and what our thinking was regarding that group within the 900 patients, that pediatric segment. It seems Josh is going to say a few words on that.

Joshua Schafer

executive
#15

Yeah. When you look at the total addressable market and what that broader label covering potentially 24 and under would add, it isn't a big number of extra patients. We're likely talking somewhere around 5%. Still, that matters a great deal to us, since it reflects our label continuing to widen and our capacity to extend access to a growing number of patients. So that's something we're quite enthusiastic about. As far as absolute figures go, it does contribute to market growth, though the patient population involved is fairly small.

Sumant Kulkarni

analyst
#16

Understood. So, with Shionogi buying IntraBio, how do you see the competitive landscape shifting in the NPC market? And what do you think could be the key to the EMA possibly overturning its prior decision on arimoclomol during this reexamination?

Neil McFarlane

executive
#17

All right, perhaps I'll take the last question first, and then I'll have Josh speak briefly about more companies entering the marketplace, which we view as a positive. Sumant, I'll keep my remarks guarded concerning the ongoing activities with the AHEG that I mentioned, as well as the CHMP opinion. There's a great deal more to say about how we remain confident in the entirety of our data package. That confidence rests on the substantial unmet need and on the fact that these experts are now coming forward who can genuinely weigh in on the clinical meaningfulness and statistical relevance of our data. So with that, I'd ask you to stay tuned, and we still anticipate our opinion in Q4. Josh, would you like to say a few words about the additional companies entering the NPC space?

Joshua Schafer

executive
#18

Yes. So for several reasons, we see this as a genuinely positive development. First, I believe it confirms our point that the market opportunity is bigger, and it really confirms there's space for continued growth inside the NPC marketplace. We hold Shionogi in high regard, and we think this is good for patients broadly, and it's going to help raise awareness and diagnosis. And importantly, this helps strengthen MIPLYFFA's solid foundational position, since we are the only drug with data demonstrating that we work in combination with miglustat. And we know combination therapies represent the fastest-growing segment of the market and are backed by the consensus guidelines. So on the whole, I view this as a very positive thing for the market.

Neil McFarlane

executive
#19

I might add a bit to that, since we do believe that part of the market's overall growth and the rise in newly diagnosed patients stems from the fact that a number of companies are putting money into Disease State Awareness. And we've observed that in the year-over-year figures from the claims data alone, and in the count of patients newly diagnosed in 2026 compared with patients in earlier years; so we're quite fortunate to have the investment that is lifting the NPC marketplace. And again, as Josh mentioned, the estimated figure we believe for the market of those diagnosed patients is now higher than what previous numbers showed. We're going to go test it and get it out there; but now, with the other folks entering the marketplace, we think the strength of our data lets us address it faster.

Truman Dunkley

analyst
#20

This is Truman, speaking in place of Lachlan. Congratulations on the quarter. You mentioned the SD&A for my filing — do you expect any further data will be required for it, or will it be ready to go?

Neil McFarlane

executive
#21

The feedback we got after our pediatric substudy is shaping how we approach our submission strategy. I won't go into the specific data, but we're confident that we can file an sNDA in Q1 of 2027.

Brandon Folkes

analyst
#22

Congratulations on yet another strong quarter. I have a few questions, if that's alright. I realize this one may be hard to answer, but I understand you don't contract and much goes through medical exception. Could you discuss what trend you're observing for net realized price per patient on therapy? Has it gone up over the year? Has it stayed fairly stable? And does that differ for a patient receiving multimodal therapy?

Neil McFarlane

executive
#23

Let me begin with that one and tell you that we still see very strong reimbursement rates across both our covered lives and the medical exception, with the strength of our data driving many of those decisions. That said, I'll turn it to Josh for some of the specifics you asked about.

Joshua Schafer

executive
#24

Yes. So we're still seeing reimbursement rates that are really strong. We're still seeing really strong refill rates, very much like what we saw in the expanded access programs; so I think that's largely driven by the strength of our clinical data and the work our team is doing to get in front of payers. We have data showing that we work in combination with miglustat. So certainly, that helps support that reimbursement as well as the long-term efficacy data that we've been able to present publicly; so all that really lends itself to continued high reimbursement and retention and refill rates; and yes, we don't see any change in that.

Neil McFarlane

executive
#25

Yes. And to be specific, we do see the patient enrollment forms coming in for MIPLYFFA, and we see what the enrollments actually are and how high a level of those enrollments go on to commercial product. What we can't answer for you is what happens with anybody else.

Brandon Folkes

analyst
#26

And perhaps picking up where an earlier question left off. Given how the market dynamic is shifting with Shionogi and the possibility of more competitors, does that alter your thinking on sales and marketing spending in 2027? I know you mentioned that the collective investments are sort of a rising tide. But how do you see your spend in 2027?

Neil McFarlane

executive
#27

I'll perhaps hand that to Justin shortly. But as for us, we've been extremely disciplined when it comes to execution, and I expect we'll keep doing that. That said, we may not give the full guidance for 2027, Brandon, on the SG&A. But Justin, would you like to speak a little about that?

Justin Renz

executive
#28

Thanks. Given the slight increase planned for next year, we don’t expect anything significant above this year’s level. So, to repeat what Neil said, our financial position is strong. We’ve got both the capacity and the flexibility. Still, I wouldn’t expect us to make substantial adjustments to marketing spend as we move ahead.

Jason Butler

analyst
#29

Nice work on the quarter. Could you describe what the newly diagnosed patients you're seeing enrollments for look like, in terms of age and how severe their disease is? And does any evidence suggest diagnosis is actually speeding up across the population? And more specifically, are some of these patients coming straight from your genetic testing expansion efforts?

Neil McFarlane

executive
#30

Great. Those are a lot of really good, specific questions that are perfect for Josh. But on the whole, I think we're quite — going back to the learning, every day we're learning what this market looks like. But really, it's the newly diagnosed patients that give us a lot of confidence this market is bigger than the 350 and somewhere between 350 and 900.

Joshua Schafer

executive
#31

Yes. I wish I could offer some kind of broad description of these newly diagnosed patients, but honestly they span the whole marketplace. So we do see older patients. We also see younger ones. A lot of them have arrived via genetic testing, through our partnership with several of those genetic testing providers. I think part of it simply stems from our work to really raise disease awareness; so there isn't any real overarching characteristic I can give you.

Neil McFarlane

executive
#32

Jason, I think with this, as with anything, there's no single fix. What we have is an integrated strategy, and we need to unlock earlier diagnosis through awareness of disease state, be able to give physicians treatment options, and make that education genuinely easy to access. And we see a chance to educate more people now, which is why we did this modest expansion — because we see a larger pool of potential patients out there based on what we've uncovered so far. And then finally, we want to make sure we keep providing access; those are three things we've invested in, and I think the team is doing an outstanding job on that; but it's difficult when your numbers are so small to give you characteristics that might be meaningful, apart from what I've said on previous calls. We always believed this disease was somewhat more of a childhood-level disease. And the fact that we still see a fairly consistent 50% kids, 50% adults and newly diagnosed in the same kind of ratios; those are learnings for us that we're now building on so we can go out and make sure we can do more disease state awareness, get patients diagnosed earlier and then provide access to them.

Eddie Hickman

analyst
#33

You said adults with milder disease make up about half of enrollments. In the 13 forms this quarter, how did the adult share in community practice compare with the first half? And given that the bottleneck seems to be getting new clinicians rather than finding patients, do you believe you'd need a bigger field team or more medical affairs spending to reach those milder adult patients? Then on the sNDA, how many patients under 24 months do you think you could add to the TAM?

Neil McFarlane

executive
#34

All right. I'll handle the first question and the last question. I'll have Josh weigh in on the middle one. Eddie, thanks for asking that. Let me make one point very clear. Just because someone is an adult patient, that doesn't mean their disease is automatically milder. What we see in the trajectory and natural history is that every patient keeps progressing, and it's actually not uncommon for an adult who has moved very slowly for a long time to then experience a change that causes them to progress much faster and be more affected. So I don't want this to — and I hope it doesn't sound like I'm saying that being an adult patient implies a milder course; that isn't always true. Everyone should keep in mind that adults, too, must show neurological involvement before MIPLYFFA can be prescribed for them — and these patients do have neurological involvement. So we're learning from the adults we're seeing, who account for roughly 50% of the prescription enrollment forms we currently have. A number of them had been given incorrect diagnoses for other conditions. One recent case involved someone wrongly diagnosed with multiple sclerosis who eventually, many years afterward, received an NPC diagnosis confirmed through genetic testing. That patient's disease was progressing. We come across many cases like this—what I'm sharing is merely a single example among numerous others, since, as you're aware, knowing one patient means knowing just one patient. That was one instance, then. Both adults and children can experience highly aggressive forms of the disease. I want to make that point clear. The following topic I'd like to discuss with you is the sNDA. Through our sNDA, there's a chance to broaden the label, and we believe these patients currently fall within the 900-patient prevalent population. As we keep seeing patients who’ve just received a diagnosis, our goal was to give doctors a clear grasp of how these products should be used, and also to help the payer community understand ways to make access to the product simpler for them. So this isn’t really about expanding the TAM itself or the prevalence itself; rather, it reflects the growing confidence we have regarding the count of diagnosed patients, which we think is estimated to be bigger than the original 300 to 350 we had.

Joshua Schafer

executive
#35

Yes. Now, regarding how large the team needs to be to reach these additional patients — that comes from our analysis and a growing grasp of the claims data. And what truly pleased me was our success in finding that more patients exist with an NPC diagnosis; and very quickly, we managed a modest expansion of the team, yet we pulled it off extremely fast so we could respond to that fresh picture of the marketplace. I believe this is a model we will embrace — one that lets us grow or shrink as we gain further knowledge about the market and as we find these patients; so I think we are appropriately sized for where we stand today, but I am genuinely pleased with how swiftly we can pivot when the data calls for it.

Kambiz Yazdi

analyst
#36

Beyond the IP strengthening and the potential label expansion you brought up for your 24 months, can you give any insight into what the next tier of life cycle management for the MIPLYFFA franchise could look like? Are there formulation, combination, or next-generation compound approaches in the pipeline that we should be considering over a longer-term horizon?

Neil McFarlane

executive
#37

Yes. Thanks, Kambiz, and I appreciate the question. As I said, I believe, on one of the earlier calls this year, we looked at our Orange Book listing going out to 2041, along with strengthening the moat of our patent portfolio with the patent term extension and the continued investments that we're looking at. Beyond that, there's potential to investigate further indications or other areas worth pursuing. At this point it's simply too soon for us to report back to you with anything concrete. That said, I want to note that we continually look for ways to get the most out of the franchise and even give NPC patients additional options.

Neil McFarlane

executive
#38

We appreciate your participation on today's call, and we're eager to continue updating you on how we advance going forward.

Operator

operator
#39

Thanks. That takes us to the close of today's meeting. We appreciate the time you've given and your participation. You may disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Zevra Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Zevra Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Zevra Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.